SpyGlass Pharma, Inc. (SGP)
NASDAQ: SGP · Real-Time Price · USD
21.18
+2.37 (12.60%)
At close: Jun 26, 2026, 4:00 PM EDT
21.15
-0.03 (-0.14%)
After-hours: Jun 26, 2026, 4:53 PM EDT

Company Description

SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions.

The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients.

It also develops a non-IOL-based, ring-shaped, sustained-release implant with bimatoprost. SpyGlass Pharma, Inc. was formerly known as SpyGlass Ophthalmics, Inc. and changed its name to SpyGlass Pharma, Inc. in April 2021.

The company was incorporated in 2019 and is based in Aliso Viejo, California.

SpyGlass Pharma, Inc.
SpyGlass Pharma logo
Country United States
Founded 2019
IPO Date Feb 6, 2026
Industry Biotechnology
Sector Healthcare
Employees 68
CEO Patrick Mooney

Contact Details

Address:
27061 Aliso Creek Road, Suite 100
Aliso Viejo, California 92656
United States
Phone 949 284 6904
Website spyglasspharma.com

Stock Details

Ticker Symbol SGP
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $16.00
CIK Code 0001778922
CUSIP Number 85220G109
ISIN Number US85220G1094
Employer ID 83-3044245
SIC Code 3841

Key Executives

Name Position
Patrick H. Mooney Chief Executive Officer and Director
Dr. Malik Y. Kahook M.D. Co-Founder, President, Chief Medical Officer and Executive Chairman
Dr. Chetan Pujara Ph.D. Chief Research and Development Officer
Glenn Sussman Co-founder and Chief Technology Advisor
Dr. Jean-Frederic Viret Ph.D. Chief Financial Officer
James Robert Dennewill Jr. Chief Operating Officer

Latest SEC Filings

Date Type Title
May 14, 2026 10-Q Quarterly Report
May 14, 2026 8-K Current Report
Mar 26, 2026 10-K Annual Report
Mar 26, 2026 8-K Current Report
Mar 9, 2026 8-K Current Report
Feb 17, 2026 SCHEDULE 13G Filing
Feb 17, 2026 SCHEDULE 13D Filing
Feb 13, 2026 SCHEDULE 13D Filing
Feb 13, 2026 SCHEDULE 13D Filing
Feb 13, 2026 8-K Current Report